Orchestra Biomed Hldgs Inc (OBIO)

$4.31 +0.16 (3.86%)
Market Cap 243.36M
Revenue (ttm) 2.64M
Net Income (ttm) -61.02M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE N/A
Profit Margin -2,311.36%
Debt to Equity Ratio 0.32
Volume 169,800
Avg Vol 271,282
Day's Range N/A - N/A
Shares Out 56.47M
Stochastic %K 68%
Beta 0.63
Analysts Strong Sell
Price Target $13.57

Company Profile

Orchestra BioMed Holdings, Inc. operates as a biomedical company in the United States. The company's flagship product candidates include Atrioventricular Interval Modulation, a bioelectronic therapy candidate designed to immediately, substantially, and persistently lower blood pressure; and Virtue Sirolimus AngioInfusion Balloon for the treatment of atherosclerotic artery disease. It also develops Cardiac Neuromodulation Therapy for heart failure, or potential treatment of clinical indications;...

Industry: Biotechnology
Sector: Healthcare
Phone: 215 862 5797
Address:
150 Union Square Drive, New Hope, United States
OfficialStocktwitsUser
OfficialStocktwitsUser Jan. 1 at 11:26 AM
$OBIO RSI: 25.93, MACD: -0.0406 Vol: 0.19, MA20: 4.40, MA50: 4.29 ⚪ HOLD - Sideways 👉 https://quantumstockalerts.com Disclaimer: I am not a financial advisor. This post reflects personal analysis and opinions only. Please do your own research before investing or trading.
0 · Reply
BinaryLogic
BinaryLogic Dec. 27 at 6:02 PM
$OBIO $MDT $LGND
0 · Reply
SuperGreenToday
SuperGreenToday Dec. 16 at 9:24 PM
$OBIO Share Price: $4.45 Contract Selected: May 15, 2026 $5 Calls Buy Zone: $0.34 – $0.42 Target Zone: $0.61 – $0.75 Potential Upside: 70% ROI Time to Expiration: 149 Days | Updates via https://fxcapta.com/stockinfo/
0 · Reply
Deeppan
Deeppan Dec. 14 at 7:34 PM
$OBIO yes
0 · Reply
GoCubsGo1124
GoCubsGo1124 Dec. 13 at 1:44 PM
$OBIO was the drop back in the late summer due to an offering?
0 · Reply
BinaryLogic
BinaryLogic Dec. 11 at 2:22 AM
$OBIO [Again] Partnerships with $MDT and $LGND, 137 global patents, breakthrough device designation, Cash runway to 1H-2027 with $95M Cash/ST against $61M Total Liabilities. Avg PT: $13.8 and currently trading at $4.75. TD Cowen just provided its forecast (PT) at $15. https://www.stocktitan.net/news/OBIO/orchestra-bio-med-announces-avim-therapy-and-virtue-sab-program-7359wz18v149.html
0 · Reply
Lambster2
Lambster2 Dec. 10 at 6:39 PM
$OBIO Doubled up at 4.55 Will add on weakness.
0 · Reply
JarvisFlow
JarvisFlow Dec. 10 at 4:03 PM
TD Cowen has updated their rating for Orchestra BioMed Hldgs ( $OBIO ) to Buy with a price target of 15.
0 · Reply
Lambster2
Lambster2 Dec. 10 at 2:40 PM
$OBIO Starter at 4.40
0 · Reply
Lambster2
Lambster2 Dec. 10 at 11:13 AM
$OBIO Orchestra BioMed (NASDAQ: OBIO) Buy (1) ESG Score: 67/100 Price Target: $15.00 Initiating At Buy: Orchestra Biomed - Composing A High-Margin Royalty Model THE TD COWEN INSIGHT OBIO is building a differentiated, royalty-based Med Tech model anchored by AVIM therapy for hypertension and Virtue SAB for arterial atherosclerotic disease. Both programs target large, underserved markets, leverage blue-chip partners, and offer scalable, high-margin economics as pivotal data and commercialization milestones approach.
0 · Reply
Latest News on OBIO
Orchestra BioMed Announces AVIM Therapy and Virtue SAB Program Presentations at ICI Meeting

Dec 8, 2025, 7:00 AM EST - 27 days ago

Orchestra BioMed Announces AVIM Therapy and Virtue SAB Program Presentations at ICI Meeting

Orchestra BioMed Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Nov 26, 2025, 4:05 PM EST - 5 weeks ago

Orchestra BioMed Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Orchestra BioMed to Participate in Upcoming Institutional Investor Conferences

Nov 11, 2025, 9:00 AM EST - 7 weeks ago

Orchestra BioMed to Participate in Upcoming Institutional Investor Conferences

MDT

Orchestra BioMed Reports Third Quarter 2025 Financial Results and Highlights Recent Business Updates

Nov 10, 2025, 4:10 PM EST - 7 weeks ago

Orchestra BioMed Reports Third Quarter 2025 Financial Results and Highlights Recent Business Updates

Orchestra BioMed to Host Business Update Call on November 12, 2025

Nov 3, 2025, 8:00 AM EST - 2 months ago

Orchestra BioMed to Host Business Update Call on November 12, 2025

MDT

Orchestra BioMed and Terumo Enter into New $30 Million Virtue SAB Strategic Agreements

Oct 28, 2025, 8:00 AM EDT - 2 months ago

Orchestra BioMed and Terumo Enter into New $30 Million Virtue SAB Strategic Agreements

Orchestra BioMed Announces First Patients Enrolled in Virtue® SAB US Pivotal IDE Coronary Trial

Oct 27, 2025, 9:00 AM EDT - 2 months ago

Orchestra BioMed Announces First Patients Enrolled in Virtue® SAB US Pivotal IDE Coronary Trial

Orchestra BioMed to Showcase Transformative Potential of AVIM Therapy in Keynote Presentation on Hypertensive Heart Disease at Georgia Innovation Summit

Oct 9, 2025, 8:00 AM EDT - 3 months ago

Orchestra BioMed to Showcase Transformative Potential of AVIM Therapy in Keynote Presentation on Hypertensive Heart Disease at Georgia Innovation Summit

MDT

Orchestra BioMed Presents New AVIM Therapy Clinical Data at HRX Demonstrating Substantial and Sustained Blood Pressure Reductions that are Reproducible Upon Reactivation Following Washout

Sep 4, 2025, 5:00 PM EDT - 4 months ago

Orchestra BioMed Presents New AVIM Therapy Clinical Data at HRX Demonstrating Substantial and Sustained Blood Pressure Reductions that are Reproducible Upon Reactivation Following Washout

Orchestra BioMed Announces Publication of Clinical Data Demonstrating Favorable Blood Pressure and Hemodynamic Effects of AVIM Therapy in JACC: Clinical Electrophysiology

Aug 26, 2025, 7:30 AM EDT - 4 months ago

Orchestra BioMed Announces Publication of Clinical Data Demonstrating Favorable Blood Pressure and Hemodynamic Effects of AVIM Therapy in JACC: Clinical Electrophysiology

Orchestra BioMed Announces Publication of AVIM Therapy Clinical Data in JACC: Advances Demonstrating Potential to Improve Cardiac Function in Patients with Hypertension and Diastolic Dysfunction

Aug 14, 2025, 8:00 AM EDT - 5 months ago

Orchestra BioMed Announces Publication of AVIM Therapy Clinical Data in JACC: Advances Demonstrating Potential to Improve Cardiac Function in Patients with Hypertension and Diastolic Dysfunction

Orchestra BioMed Reports Second Quarter 2025 Financial Results and Highlights Recent Business Updates

Aug 12, 2025, 8:14 AM EDT - 5 months ago

Orchestra BioMed Reports Second Quarter 2025 Financial Results and Highlights Recent Business Updates

Orchestra BioMed Announces Rollout of FDA-Approved BACKBEAT Global Pivotal Study Protocol Update Significantly Expanding Patient Eligibility

Aug 8, 2025, 7:00 AM EDT - 5 months ago

Orchestra BioMed Announces Rollout of FDA-Approved BACKBEAT Global Pivotal Study Protocol Update Significantly Expanding Patient Eligibility

Orchestra BioMed Secures Over $111 Million in Proceeds and Committed Capital Following Completion of Strategic Transactions and Concurrent Public and Private Equity Offerings

Aug 5, 2025, 7:00 AM EDT - 5 months ago

Orchestra BioMed Secures Over $111 Million in Proceeds and Committed Capital Following Completion of Strategic Transactions and Concurrent Public and Private Equity Offerings

Orchestra BioMed Announces Pricing of $40 Million Public Offering

Aug 1, 2025, 7:59 AM EDT - 5 months ago

Orchestra BioMed Announces Pricing of $40 Million Public Offering

Orchestra BioMed Announces Proposed Public Offering

Jul 31, 2025, 4:02 PM EDT - 5 months ago

Orchestra BioMed Announces Proposed Public Offering

Ligand and Medtronic Commit $70 Million in Strategic Capital to Orchestra BioMed

Jul 31, 2025, 4:01 PM EDT - 5 months ago

Ligand and Medtronic Commit $70 Million in Strategic Capital to Orchestra BioMed

LGND MDT

Orchestra BioMed Showcases AVIM Therapy as Purpose-Built Solution for Hypertensive Heart Disease at CSI Frankfurt 2025

Jun 18, 2025, 9:30 AM EDT - 7 months ago

Orchestra BioMed Showcases AVIM Therapy as Purpose-Built Solution for Hypertensive Heart Disease at CSI Frankfurt 2025

Orchestra BioMed: Two Best-In-Class Devices And Promising Partnerships

May 28, 2025, 7:20 AM EDT - 7 months ago

Orchestra BioMed: Two Best-In-Class Devices And Promising Partnerships

Orchestra BioMed Reports First Quarter 2025 Financial Results and Highlights Recent Regulatory and Clinical Milestones

May 12, 2025, 4:28 PM EDT - 8 months ago

Orchestra BioMed Reports First Quarter 2025 Financial Results and Highlights Recent Regulatory and Clinical Milestones

Orchestra BioMed's AVIM Therapy Global Intellectual Property Estate Reaches 137 Issued Patents for the Treatment of Hypertension and Heart Failure

May 7, 2025, 8:30 AM EDT - 8 months ago

Orchestra BioMed's AVIM Therapy Global Intellectual Property Estate Reaches 137 Issued Patents for the Treatment of Hypertension and Heart Failure

Orchestra BioMed Receives FDA Approval of IDE to Initiate U.S. Coronary Pivotal Trial Randomizing First-in-Class Sirolimus-AngioInfusion Balloon, Virtue SAB, Head-to-Head with Paclitaxel-Coated Balloon

Apr 29, 2025, 9:00 AM EDT - 8 months ago

Orchestra BioMed Receives FDA Approval of IDE to Initiate U.S. Coronary Pivotal Trial Randomizing First-in-Class Sirolimus-AngioInfusion Balloon, Virtue SAB, Head-to-Head with Paclitaxel-Coated Balloon

Orchestra BioMed Announces AVIM Therapy-Focused Satellite Symposium at HRS 2025 Annual Meeting

Apr 23, 2025, 9:00 AM EDT - 9 months ago

Orchestra BioMed Announces AVIM Therapy-Focused Satellite Symposium at HRS 2025 Annual Meeting

MDT

Orchestra BioMed Receives FDA Breakthrough Device Designation for AVIM Therapy

Apr 22, 2025, 7:00 AM EDT - 9 months ago

Orchestra BioMed Receives FDA Breakthrough Device Designation for AVIM Therapy

Orchestra BioMed Reports Full Year 2024 Financial Results and Provides a Fourth Quarter Business Update

Mar 31, 2025, 4:21 PM EDT - 9 months ago

Orchestra BioMed Reports Full Year 2024 Financial Results and Provides a Fourth Quarter Business Update

Orchestra BioMed to Present at Upcoming Investor Conferences

Feb 20, 2025, 8:00 AM EST - 11 months ago

Orchestra BioMed to Present at Upcoming Investor Conferences

Orchestra BioMed Appoints Vivek Reddy, M.D. as Executive Chairman of the BACKBEAT Study Steering Committee and Chairman of Bioelectronic Therapies Scientific Advisory Board

Feb 18, 2025, 8:00 AM EST - 11 months ago

Orchestra BioMed Appoints Vivek Reddy, M.D. as Executive Chairman of the BACKBEAT Study Steering Committee and Chairman of Bioelectronic Therapies Scientific Advisory Board

Orchestra BioMed Announces Data Demonstrating Favorable Impact of AVIM Therapy on Diastolic Dysfunction, a Key Driver of Heart Failure Progression, will be Presented as Late-Breaking Science at the THT 2025 Conference

Feb 12, 2025, 10:43 AM EST - 11 months ago

Orchestra BioMed Announces Data Demonstrating Favorable Impact of AVIM Therapy on Diastolic Dysfunction, a Key Driver of Heart Failure Progression, will be Presented as Late-Breaking Science at the THT 2025 Conference

Orchestra BioMed Announces Appointment of Former Medtronic SVP of Corporate Development Christopher Cleary to Board of Directors

Feb 5, 2025, 8:00 AM EST - 11 months ago

Orchestra BioMed Announces Appointment of Former Medtronic SVP of Corporate Development Christopher Cleary to Board of Directors

Orchestra BioMed to Participate in the Piper Sandler 36th Annual Healthcare Conference

Nov 26, 2024, 4:05 PM EST - 1 year ago

Orchestra BioMed to Participate in the Piper Sandler 36th Annual Healthcare Conference

Orchestra BioMed Reports Third Quarter 2024 Financial Results and Provides a Business Update

Nov 12, 2024, 4:12 PM EST - 1 year ago

Orchestra BioMed Reports Third Quarter 2024 Financial Results and Provides a Business Update

Orchestra BioMed Reports Second Quarter 2024 Financial Results and Provides a Business Update

Aug 12, 2024, 4:20 PM EDT - 1 year ago

Orchestra BioMed Reports Second Quarter 2024 Financial Results and Provides a Business Update

Orchestra BioMed to Participate in Jefferies Global Healthcare Conference

May 22, 2024, 8:43 AM EDT - 1 year ago

Orchestra BioMed to Participate in Jefferies Global Healthcare Conference

Orchestra BioMed Reports First Quarter 2024 Financial Results and Provides a Business Update

May 13, 2024, 4:58 PM EDT - 1 year ago

Orchestra BioMed Reports First Quarter 2024 Financial Results and Provides a Business Update

Orchestra BioMed Announces AVIM Therapy Global Intellectual Property Estate Reaches 110 Issued Patents

Apr 30, 2024, 8:30 AM EDT - 1 year ago

Orchestra BioMed Announces AVIM Therapy Global Intellectual Property Estate Reaches 110 Issued Patents

Orchestra BioMed Reports Full Year 2023 Financial Results and Provides Fourth Quarter Business Update

Mar 27, 2024, 4:17 PM EDT - 1 year ago

Orchestra BioMed Reports Full Year 2023 Financial Results and Provides Fourth Quarter Business Update

Orchestra BioMed Announces Appointment of Medical Device Industry Expert David Pacitti to Board of Directors

Mar 26, 2024, 8:00 AM EDT - 1 year ago

Orchestra BioMed Announces Appointment of Medical Device Industry Expert David Pacitti to Board of Directors

Orchestra BioMed to Participate in Upcoming Investor Conferences

Mar 7, 2024, 8:00 AM EST - 1 year ago

Orchestra BioMed to Participate in Upcoming Investor Conferences

Orchestra BioMed Announces Presentation of Results from Clinical Study Demonstrating Favorable Hemodynamic Effects of AVIM Therapy In Hypertensive Pacemaker Patients

Mar 6, 2024, 8:37 AM EST - 1 year ago

Orchestra BioMed Announces Presentation of Results from Clinical Study Demonstrating Favorable Hemodynamic Effects of AVIM Therapy In Hypertensive Pacemaker Patients

Orchestra BioMed Announces Initiation of BACKBEAT Pivotal Study of AVIM Therapy in Hypertensive Pacemaker Patients

Jan 8, 2024, 7:30 AM EST - 2 years ago

Orchestra BioMed Announces Initiation of BACKBEAT Pivotal Study of AVIM Therapy in Hypertensive Pacemaker Patients

Orchestra BioMed Reports Third Quarter 2023 Financial Results and Provides Business Update

Nov 13, 2023, 4:21 PM EST - 2 years ago

Orchestra BioMed Reports Third Quarter 2023 Financial Results and Provides Business Update

Orchestra BioMed Granted FDA Approval of IDE to Initiate BACKBEAT Pivotal Study of BackBeat CNT™ for the Treatment of Hypertension in Pacemaker Patients

Sep 19, 2023, 7:30 AM EDT - 2 years ago

Orchestra BioMed Granted FDA Approval of IDE to Initiate BACKBEAT Pivotal Study of BackBeat CNT™ for the Treatment of Hypertension in Pacemaker Patients

Orchestra BioMed Reports Second Quarter 2023 Financial Results and Provides Business Update

Aug 10, 2023, 4:34 PM EDT - 2 years ago

Orchestra BioMed Reports Second Quarter 2023 Financial Results and Provides Business Update

Orchestra BioMed™ Granted FDA Approval of IDE for U.S. Pivotal Study of Virtue® Sirolimus AngioInfusion Balloon™ in Patients with Coronary In-Stent Restenosis

Aug 8, 2023, 8:30 AM EDT - 2 years ago

Orchestra BioMed™ Granted FDA Approval of IDE for U.S. Pivotal Study of Virtue® Sirolimus AngioInfusion Balloon™ in Patients with Coronary In-Stent Restenosis

Orchestra BioMed Set to Join Russell 3000® and other FTSE Russell Indexes

Jun 26, 2023, 8:00 AM EDT - 2 years ago

Orchestra BioMed Set to Join Russell 3000® and other FTSE Russell Indexes

Orchestra BioMed Appoints Bill Little as Executive Vice President of Corporate Development and Strategy and Andrew Taylor as Chief Financial Officer

Jun 7, 2023, 8:30 AM EDT - 2 years ago

Orchestra BioMed Appoints Bill Little as Executive Vice President of Corporate Development and Strategy and Andrew Taylor as Chief Financial Officer

Orchestra BioMed Reports First Quarter 2023 Financial Results and Provides Business Update

May 12, 2023, 9:15 AM EDT - 2 years ago

Orchestra BioMed Reports First Quarter 2023 Financial Results and Provides Business Update

Orchestra BioMed Announces Upcoming Presentations on BackBeat CNT™ and Virtue® SAB at CRT 2023

Feb 24, 2023, 8:00 AM EST - 3 years ago

Orchestra BioMed Announces Upcoming Presentations on BackBeat CNT™ and Virtue® SAB at CRT 2023

Orchestra BioMed Debuts as Nasdaq-Traded Company with Lead Programs Targeting Hypertension and Artery Disease and Novel Partnership-Enabled Business Model

Jan 27, 2023, 8:00 AM EST - 3 years ago

Orchestra BioMed Debuts as Nasdaq-Traded Company with Lead Programs Targeting Hypertension and Artery Disease and Novel Partnership-Enabled Business Model

Orchestra BioMed™ Announces Strategic Collaboration, Closing of $110 Million Private Equity Financing and Plans to List on Nasdaq Through Merger with Health Sciences Acquisitions Corporation 2

Jul 5, 2022, 8:00 AM EDT - 3 years ago

Orchestra BioMed™ Announces Strategic Collaboration, Closing of $110 Million Private Equity Financing and Plans to List on Nasdaq Through Merger with Health Sciences Acquisitions Corporation 2

OfficialStocktwitsUser
OfficialStocktwitsUser Jan. 1 at 11:26 AM
$OBIO RSI: 25.93, MACD: -0.0406 Vol: 0.19, MA20: 4.40, MA50: 4.29 ⚪ HOLD - Sideways 👉 https://quantumstockalerts.com Disclaimer: I am not a financial advisor. This post reflects personal analysis and opinions only. Please do your own research before investing or trading.
0 · Reply
BinaryLogic
BinaryLogic Dec. 27 at 6:02 PM
$OBIO $MDT $LGND
0 · Reply
SuperGreenToday
SuperGreenToday Dec. 16 at 9:24 PM
$OBIO Share Price: $4.45 Contract Selected: May 15, 2026 $5 Calls Buy Zone: $0.34 – $0.42 Target Zone: $0.61 – $0.75 Potential Upside: 70% ROI Time to Expiration: 149 Days | Updates via https://fxcapta.com/stockinfo/
0 · Reply
Deeppan
Deeppan Dec. 14 at 7:34 PM
$OBIO yes
0 · Reply
GoCubsGo1124
GoCubsGo1124 Dec. 13 at 1:44 PM
$OBIO was the drop back in the late summer due to an offering?
0 · Reply
BinaryLogic
BinaryLogic Dec. 11 at 2:22 AM
$OBIO [Again] Partnerships with $MDT and $LGND, 137 global patents, breakthrough device designation, Cash runway to 1H-2027 with $95M Cash/ST against $61M Total Liabilities. Avg PT: $13.8 and currently trading at $4.75. TD Cowen just provided its forecast (PT) at $15. https://www.stocktitan.net/news/OBIO/orchestra-bio-med-announces-avim-therapy-and-virtue-sab-program-7359wz18v149.html
0 · Reply
Lambster2
Lambster2 Dec. 10 at 6:39 PM
$OBIO Doubled up at 4.55 Will add on weakness.
0 · Reply
JarvisFlow
JarvisFlow Dec. 10 at 4:03 PM
TD Cowen has updated their rating for Orchestra BioMed Hldgs ( $OBIO ) to Buy with a price target of 15.
0 · Reply
Lambster2
Lambster2 Dec. 10 at 2:40 PM
$OBIO Starter at 4.40
0 · Reply
Lambster2
Lambster2 Dec. 10 at 11:13 AM
$OBIO Orchestra BioMed (NASDAQ: OBIO) Buy (1) ESG Score: 67/100 Price Target: $15.00 Initiating At Buy: Orchestra Biomed - Composing A High-Margin Royalty Model THE TD COWEN INSIGHT OBIO is building a differentiated, royalty-based Med Tech model anchored by AVIM therapy for hypertension and Virtue SAB for arterial atherosclerotic disease. Both programs target large, underserved markets, leverage blue-chip partners, and offer scalable, high-margin economics as pivotal data and commercialization milestones approach.
0 · Reply
Mptxop
Mptxop Dec. 5 at 4:24 PM
$OBIO I was hoping for a bounce. If it falls more it’s going to fall more!
0 · Reply
Mptxop
Mptxop Dec. 3 at 4:11 PM
$OBIO we may see a little more downward movement before it goes back to 6$.
0 · Reply
ppl_first
ppl_first Nov. 26 at 4:00 PM
$OBIO was able to sell today, no loss, no gain. Volume really tells the story, not the news. There isn’t any volume to speak of.
0 · Reply
ppl_first
ppl_first Nov. 26 at 12:50 AM
$OBIO oh shit! Got ‘em. Nice rug pull on us retail bag holders. Selling at another loss.
1 · Reply
ppl_first
ppl_first Nov. 25 at 9:59 PM
$OBIO Can't hold its own after hours, scary for tomorrow morning.
0 · Reply
RunnerSignals
RunnerSignals Nov. 25 at 9:18 PM
Comeback Kings Alert 🔥 $CIFR $OBIO $ADI $PACB $LAES bounced HARD from session lows! One rallied 10%+ from the bottom https://stocksrunner.com/news/2025-11-25-10-stocks-that-refused-to-stay-down-today
0 · Reply
Pkinla
Pkinla Nov. 25 at 8:12 PM
$OBIO what’s cooking !?
1 · Reply
ppl_first
ppl_first Nov. 25 at 7:19 PM
$OBIO The company announced they secured over $111 million in proceeds and committed capital from strategic investors, which strengthens the balance sheet and runway.
0 · Reply
ppl_first
ppl_first Nov. 25 at 7:17 PM
$OBIO OBIO does not look like a dilution trap. They have real cash, real investment backing, and a multi-year runway. That said, I'm in at 5.28 with a tight stop loss at 5.20.
0 · Reply
ppl_first
ppl_first Nov. 25 at 7:12 PM
$OBIO 32M float $42 million in cash and equivalents $53.8 million in marketable securities $30 million strategic investment announced afterward Total accessible capital: roughly $125–$130 million. This is not a distressed microcap profile. This is legitimate runway.
0 · Reply
DaBullRunner
DaBullRunner Nov. 25 at 7:02 PM
$OBIO there it goes …. 🚨INM🚨adding as they have multiple catalysts coming up it deals with ALZHEIMER’S This is my next ATHE👇💰💰💰
0 · Reply
Mptxop
Mptxop Nov. 25 at 6:04 PM
$OBIO This is in beast mode!
0 · Reply